Damora Therapeutics (DMRA) director awarded 30,350 stock options at $31.00 strike
Rhea-AI Filing Summary
Damora Therapeutics, Inc. reported that director Andrew Cheng received a grant of 30,350 stock options on 2026-08-12. The options have an exercise price of $31.00 per share, are exercisable for 30,350 Ordinary Shares, and expire on 2036-08-12. They vest in equal monthly installments through August 12, 2029, subject to his continued service, and this grant brings his directly held option position to 30,350 derivative securities.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Cheng Andrew
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) F1 | 30,350 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 30,350 shares (Direct)
Footnotes (1)
- F1. This option represents a right to purchase shares of common stock of the Issuer. This option will vest in equal monthly installments through August 12, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
Key Figures
Options Granted: 30,350 options
Exercise Price: $31.00 per share
Expiration Date: 2036-08-12
+3 more
6 metrics
Options Granted
30,350 options
Stock Option (right to buy) grant on 2026-08-12
Exercise Price
$31.00 per share
Conversion or exercise price of granted options
Expiration Date
2036-08-12
Option term for stock option grant
Underlying Shares
30,350 shares
Ordinary Shares underlying the stock options
Post-transaction derivative holdings
30,350 options
Total derivative securities owned following the grant
Vesting End Date
2029-08-12
Equal monthly vesting through this date, subject to continued service
Key Terms
Stock Option (right to buy, derivative securities, exercise price, vesting
4 terms
Stock Option (right to buy financial
"security_title: Stock Option (right to buy)"
derivative securities financial
"brings his directly held option position to 30,350 derivative securities"
Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.
exercise price financial
"conversion_or_exercise_price: 31.0000"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"This option will vest in equal monthly installments"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
What did Andrew Cheng acquire in Damora Therapeutics (DMRA) according to this Form 4?
Andrew Cheng received a grant of 30,350 stock options to purchase Damora Therapeutics Ordinary Shares at an exercise price of $31.00 per share, all reported as directly owned derivative securities.
What is the vesting schedule of Andrew Cheng’s new DMRA stock options?
The 30,350 stock options vest in equal monthly installments through August 12, 2029, conditioned on Andrew Cheng’s continued service to Damora Therapeutics on each vesting date.
What is the exercise price and expiration date of Andrew Cheng’s DMRA options?
The granted options carry an exercise price of $31.00 per share and an expiration date of August 12, 2036, providing a long-term right to purchase Ordinary Shares of Damora Therapeutics.
How many Damora Therapeutics derivative securities does Andrew Cheng hold after this transaction?
Following the grant, Andrew Cheng beneficially owns 30,350 derivative securities directly, all represented by stock options exercisable for 30,350 Ordinary Shares of Damora Therapeutics.
Was Andrew Cheng’s DMRA option grant made under a Rule 10b5-1 trading plan?
The filing indicates the Rule 10b5-1 checkbox is not marked as affirmative, and there is no footnote stating these options were granted pursuant to a Rule 10b5-1 trading plan.
AI-generated analysis. How Rhea-AI works. Not financial advice.
